Insider Buying: EuroEyes International Eye Clinic Founder Bought HK$448k Of Shares
Insider Buying: EuroEyes International Eye Clinic Founder Bought HK$448k Of Shares
Even if it's not a huge purchase, we think it was good to see that Jörn Jörgensen, the Founder of EuroEyes International Eye Clinic Limited (HKG:1846) recently shelled out HK$448k to buy stock, at HK$4.39 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.
即使這不是一筆巨大的收購,我們認為看到JöRn Jörgensen,該公司的創始人歐洲眼國際眼科診所有限公司(HKG:1846)最近斥資44.8萬港元買入股票,每股4.39港元。儘管如此,他們的持股比例只增加了很小一部分,從絕對值來看,這也不是大規模收購。
See our latest analysis for EuroEyes International Eye Clinic
查看我們對歐洲眼國際眼科診所的最新分析
EuroEyes International Eye Clinic Insider Transactions Over The Last Year
歐洲眼國際眼科診所去年的內幕交易
Notably, that recent purchase by Founder Jörn Jörgensen was not the only time they bought EuroEyes International Eye Clinic shares this year. Earlier in the year, they paid HK$5.50 per share in a HK$4.4m purchase. That means that an insider was happy to buy shares at above the current price of HK$4.40. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
值得注意的是,創始人JöRn Jörgensen最近的那次收購並不是他們今年唯一次購買Euroyes國際眼科診所的股票。今年早些時候,他們以每股5.5港元的價格收購了440萬港元。這意味著,一位內部人士樂於以高於當前4.40港元的價格買入股票。自那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士為股票支付的價格非常重要。如果他們支付的價格高於當前價格,通常會更令人鼓舞,因為這表明他們看到了價值,即使是在更高的水準。
In the last twelve months EuroEyes International Eye Clinic insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
在過去的12個月裡,歐洲眼國際眼科診所的內部人士在買入股票,但沒有賣出。你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。通過點擊下面的圖表,你可以看到每一筆內幕交易的準確細節!
EuroEyes International Eye Clinic is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
歐洲眼國際眼科診所並不是業內人士唯一買入的股票。對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
Does EuroEyes International Eye Clinic Boast High Insider Ownership?
歐洲眼國際眼科診所擁有高度的內部人持股嗎?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that EuroEyes International Eye Clinic insiders own 57% of the company, worth about HK$836m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
對於一個普通股股東來說,公司內部人士持有多少股份值得一查。我認為,如果內部人士持有該公司大量股份,這是一個好兆頭。很高興看到歐洲眼國際眼科診所的內部人士持有該公司57%的股份,價值約8.36億港元。這種由內部人士持有的重大所有權通常確實增加了公司以所有股東的利益運營的機會。
So What Does This Data Suggest About EuroEyes International Eye Clinic Insiders?
那麼,這些數據對歐洲眼國際眼科診所的內部人士有什麼啟示呢?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. Once you factor in the high insider ownership, it certainly seems like insiders are positive about EuroEyes International Eye Clinic. That's what I like to see! If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
最近的內部收購令人振奮。對過去一年交易的分析也給了我們信心。一旦你考慮到內部人士的高持股比例,內部人士似乎肯定對歐洲眼國際眼科診所持積極態度。這就是我想看到的!如果你像我一樣,你可能會想一想這家公司是會增長還是會萎縮。幸運的是,你可以檢查這個免費顯示分析師對其未來預測的報告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費列出了一些有趣的公司,這些公司擁有高股本回報率和低債務。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前只處理公開市場交易和私下處置直接權益,而不處理衍生工具交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.